9C
NPCE icon

9823 Capital’s Neuropace NPCE Stock Holding History

9823 Capital’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,314
Closed -$175K – 53
2026
Q1 		$175K Buy
+13,314
New +$200K 0.13% 37

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

9823 Capital's NPCE Position: Q2 2026 in Review

9823 Capital sold out of Neuropace (NPCE) in Q2 2026, closing a stake of 13,314 shares — an estimated $175K sold.

9823 Capital first reported a position in NPCE in Q1 2026 and held it in 1 quarter. The position peaked at $175K in Q1 2026. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • 9823 Capital reported no remaining Neuropace position as of Q2 2026 after selling out during the quarter.
  • 9823 Capital sold 13,314 Neuropace shares in Q2 2026, an estimated $175K.
  • 9823 Capital first reported a position in Neuropace in Q1 2026 and held it in 1 quarter.
  • 9823 Capital's Neuropace position peaked at $175K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on 9823 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.